3Vaidya A P,Parnes A D,Seiden M V.Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies[J].Curt Treat Options Oncol,2005,6(2):103-114.
4Bellone S,Frera G,Landolfi G,et al.Overexpression of epidermal growth factor type-1 receptor(EGF-RI)in cervical cancer:implications for Cetuximab-mediated therapy in recurrent/metastatic disease[J].Gynecol Oncol,2007,106(3):513-520.
6Zerkowski M P,Camp R L,Burtness B A,et al.Quantitative analysis of breast cancer tissue micmarrays shows high COX-2 expression is associated with poor outcome[J].Cancer Invest,2007,25(1):19-26.
7Lim S C,Lee T B,Choi C H,et al.Expression of cyelooxygenase-2 and its relationship to p53 accumulation in colorectalcancers[J].Yonsei Med J,2007,48(3):495-501.Fujimoto J,Toyoki H,Sato E,et al.Expression of cyclooxygenase-2 related to angiogenesis in uterine cervical cancers[J].J Biomed Sci,2006,13(6):825-832.
8Jiang Y,Goldberg I D,Shi Y E.Complex roles of tissue inhibitors of metalloproteinases in cancer[J].Oncogene,2002,21(14):2245-2252.
9Davidson B,Goldberg I,Kopo lovic J,et al.Expression of matrix metalloprteinase-9 in squamouse cell carcinoma of the uterine cervix-clinicopathologic study using immunohistoche-mistry and mRNA in situ hybridization[J].Gynocol Oncol,1999,72(3):380-386.
10Goncalves A,Fabbro M,Lhommé C,et al.A phaseⅡtrial to evaluate gefitinih as secoud-or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer[J].Gynecol Oncol,2008,108(1):42-46.
